Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval
SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Neuronata-R®, an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), has demonstrated meaningful efficacy signals in a subgroup of participants with slow disease progression in its recently completed Phase 3 trial. The therapy also showed consistent reductions in neurofilament light chain (NfL) levels — a biomarker that served as the basis for FDA accelerated approval in ALS, including the recent decision on Tofersen — supporting its potential to pursue a similar regulatory pathway.
Developed by South Korean biotech company CorestemChemon (KOSDAQ: 166480), Neuronata-R® utilizes MSCs derived from a participant's own bone marrow to modulate inflammation, protect motor neurons, and alter the neurodegenerative microenvironment through paracrine signaling. ALS, a rare and fatal disease with no cure, remains one of the most urgent areas of unmet medical need. Neuronata-R® aims to address the disease's complex pathology by leveraging the therapeutic potential of autologous MSCs.
In December 2024, CorestemChemon announced topline results from the ALSummit trial (NCT04745299), noting that the study did not meet its primary endpoint — a combined assessment of function and survival known as CAFS — in the overall patient population. However, a post hoc analysis conducted after the completion of the trial and full data collection revealed significant clinical improvements in a subgroup of patients with slower disease progression. To discuss these findings, the company plans to meet with the U.S. Food and Drug Administration (FDA) later this year to discuss these findings, with the aim of submitting a biologics license application by the end of 2025 and potentially securing accelerated approval by mid-2026.
Subgroup Analysis Supports Targeted Efficacy
The final Clinical Study Report (CSR) confirmed that Neuronata-R® demonstrated statistically significant improvements in key efficacy endpoints among participants with slow disease progression. Recognizing the potential efficacy of Neuronata-R® in early-stage ALS, CorestemChemon stratified participants into slow and fast progressors.
Among slow progressors, Neuronata-R® showed statistically significant improvements across multiple measures — including the primary composite endpoint, CAFS (Combined Assessment of Function and Survival), functional outcomes assessed by ALSFRS-R scores, and respiratory function measured by slow vital capacity (SVC).
Notably, the five-dose treatment arm (Group 2) demonstrated statistically significant improvement in ALSFRS-R scores beginning at Month 9 post-treatment — one month earlier than the two-dose arm (Group 1), which reached significance at Month 10.
This final CSR also included full analyses of CAFS and SVC, which had not been previously disclosed. While CAFS served as the trial's primary efficacy endpoint, SVC is recognized as a clinically meaningful measure of respiratory decline in ALS.
At Month 6, participants in Group 1 receiving Neuronata-R® showed a statistically significant improvement in CAFS (LS Mean 20.95 vs 13.66; 95% CI; p<0.024) compared with placebo. Group 2 also showed improvement (LS Mean 24.78 vs 17.92; 95% CI; p<0.041). In Group 2, significant divergence in SVC compared to the control group emerged from Month 8 post-treatment, suggesting a potential effect in delaying disease progression.
NfL Biomarker Reduction Mirrors Regulatory Precedent
CorestemChemon also highlighted the reduction in NfL levels — a biomarker that served as the basis for FDA accelerated approval in ALS, including the recent decision on Tofersen. In both the two-dose (Group 1) and five-dose (Group 2) arms, NfL levels consistently declined over time. Notably, in Group 2, NfL levels were significantly lower than placebo at both Month 4 and Month 10, suggesting a potential dose-dependent effect.
The consistency between the company's internal analysis and validation by an independent CRO strengthens the reliability of the dataset, which has been incorporated into the final CSR.
"This subgroup analysis lends strong support to a biomarker-driven approval strategy," a company official said. "The consistency of our internal analysis with external CRO validation adds credibility to the dataset and provides a concrete basis for regulatory discussions with the MFDS."
Regulatory Pathway Toward Accelerated Approval
The company views these findings as strategically significant, particularly in light of their alignment with the precedent set by Tofersen, where the FDA granted accelerated approval based on NfL reduction rather than survival benefit — a pathway CorestemChemon now seeks to pursue.
The company plans to request a Pre-BLA or Type C meeting with the FDA in Q3 2025, with the goal of submitting a biologics license application by Q4 2025 and targeting regulatory approval by mid-2026. CorestemChemon will finalize its submission package in collaboration with a global CRO and actively engage with regulatory agencies to pursue worldwide market entry for Neuronata-R®.
Innovative Stem Cell Therapy
Neuronata-R® uniquely addresses the complex mechanisms of ALS by leveraging MSCs derived from the patient's own bone marrow. These cells exert anti-inflammatory and immunomodulatory effects, protect motor neurons, and, through paracrine signaling, secrete trophic factors, cytokines, and extracellular vesicles that modulate the microenvironment and reduce neuroinflammation. By targeting these underlying pathological processes, Neuronata-R ® is designed to interrupt the neurodegenerative cascade.
About Neuronata-R®
Neuronata-R® (Lenzumestrocel), developed and commercialized by CorestemChemon Inc. (KOSDAQ: 166480), is an autologous MSC therapy for ALS patients. The company began ALS research in 2002 and obtained MFDS approval for Neuronata-R® in 2014. To date, it has been administered to more than 400 commercial patients and 190 clinical trial participants with no treatment-related serious adverse events reported.
Neuronata-R® holds Orphan Drug Designation from both the U.S. FDA (2018) and the EMA (2019). CorestemChemon completed a Phase 2 trial (NCT01363401) in 2014 and its Phase 3 trial (NCT04745299) in 2024; the final CSR has been submitted to the MFDS.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
![[Yoo Choon-sik] What South Korea must see beyond US tariff deal](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F08%2F03%2Fnews-p.v1.20250803.f9e738156c1f4c549ebb73d1191ea6b4_T1.jpg&w=3840&q=100)
![[Yoo Choon-sik] What South Korea must see beyond US tariff deal](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fkoreaherald.com.png&w=48&q=75){kind=small}
Korea Herald
an hour ago
- Korea Herald
[Yoo Choon-sik] What South Korea must see beyond US tariff deal
South Korea's last-minute trade agreement with the United States — concluded just under two days before the deadline — has dominated headlines and conversations both domestically and internationally. The attention is understandable. Since the beginning of President Donald Trump's second term earlier this year, US tariff policy has emerged as one of the most destabilizing forces in the global economy. For South Korea — a country that relies heavily on manufacturing and exports — the stakes could not have been more critical. The agreement sets US tariffs on most South Korean exports at 15 percent, a significant reduction from the initially proposed 25 percent. As part of the broader deal, South Korea has committed to investing $350 billion in the United States, including a $150 billion shipbuilding fund. The remaining $200 billion will be funneled into strategic sectors including semiconductors, nuclear energy, secondary batteries and biotechnology. While further details are expected to be revealed at the forthcoming summit between the two nations' leaders, the contours of this investment commitment already signal a recalibration in South Korea's trade and industrial strategy. President Lee Jae Myung rightly hailed the deal as both a diplomatic and economic achievement. It not only lowers tariff burdens, but also removes a significant source of uncertainty. Yet while South Korea's export-led model has been the backbone of its 'economic miracle' over the past half-century, it leaves the country acutely vulnerable to shifts in global trade dynamics and foreign policy. In stark contrast to the robust manufacturing sector, South Korea's domestic service industries remain underdeveloped. Their contribution to national gross domestic product and employment continues to lag behind those of service sectors in most other advanced economies. A vibrant service sector provides a buffer against external shocks, encourages inclusive employment, enhances human development and supports long-term economic resilience. For countries like South Korea that aim for both sustained prosperity and social cohesion, building a stronger domestic service economy is not just a desirable policy goal — it is a strategic necessity. A recent report by the Bank of Korea offers a timely assessment of the nation's service sector. On the surface, there has been progress. Since the 1990s, the share of manufacturing value added in nominal GDP has plateaued in the mid-to-high 20 percent range. Meanwhile, the service sector has steadily expanded, accounting for 44 percent of nominal GDP as of 2024. The share of workers in manufacturing has declined steadily since peaking at 28 percent in 1989. By contrast, the service sector now accounts for 65 percent of all employed workers in the country. Since the 1990s, services have been the main engine of job creation, and this trend shows no signs of reversing. Since the mid-1990s, however, productivity in services has consistently lagged behind that of manufacturing, with minimal improvement over time. For more than 20 years, service sector productivity has remained stuck at just 40 percent of manufacturing productivity. Making service sectors more productive This imbalance is particularly striking when compared to other manufacturing-heavy economies. Even in Japan and Germany — nations with similarly strong industrial foundations — the productivity gap between services and manufacturing is notably smaller. The Bank of Korea identifies this chronic inefficiency as one of the primary structural bottlenecks constraining South Korea's long-term growth potential. The COVID-19 pandemic has only magnified these vulnerabilities. In the wake of the global health crisis, South Korea's economic growth rate has declined sharply relative to pre-pandemic levels. The primary driver of this slowdown has been the diminished productivity of the private service sector. This has serious implications. In a world increasingly shaped by knowledge, data and digital platforms, a country's capacity to generate high-value services is becoming as important as its ability to manufacture high-quality goods. While the US tariff deal provides welcome short-term relief, it must serve as a broader catalyst for economic transformation. South Korea now stands at a pivotal moment — facing mounting structural, demographic and geopolitical challenges. A new strategy is needed, and the Bank of Korea outlines three core imperatives. South Korea must establish a comprehensive legal and institutional foundation for industrial policy that reflects the convergence of manufacturing and services. Current regulatory systems are ill-suited to accommodate hybrid sectors and emerging business models. Bold regulatory reforms are needed to create space for innovation across sectors. South Korea has an enviable repository of intellectual assets, technical know-how and operational capabilities accumulated through decades of industrial leadership. This expertise should now be redeployed into developing AI- and data-driven industrial services. Areas such as digital content, telemedicine, logistics and smart manufacturing offer fertile ground for combining South Korea's technical strengths with global service demand. The country's economy is burdened by a disproportionately high number of small-scale, often involuntarily self-employed workers. Rather than attempting to shrink this sector, the government should expand the availability of quality jobs in larger, more stable firms. At the same time, institutional and financial support for startups and business transitions must be enhanced to inject vitality into the broader economy. As South Korea's president heads off on a well-deserved summer holiday, it is a fitting moment for reflection. The successful tariff agreement with Washington offers breathing room, but it must not foster complacency. Now is the time to convert a reactive diplomatic victory into a proactive economic strategy. South Korea must shift from a narrow export-dependent model to a more balanced and resilient growth paradigm, one that fully harnesses the potential of its service sector. The agreement with the United States must be the beginning of a new chapter — one in which external pressure sparks internal reform and short-term compromise paves the way for long-term renewal. With vision, discipline and courage, South Korea can turn this moment of relief into a lasting opportunity for transformation. The country has risen to great challenges before. It can — and must — do so again.
Korea Herald
15 hours ago
- Korea Herald
Ruling party faces backlash on tax code revision
The ruling Democratic Party of Korea is facing backlash amid speculation that Friday's sharp drop in the Korea Exchange's main board Kospi may be associated with the Lee Jae Myung government's push to impose taxes on a wider scope of investors to address the tax revenue shortfall. On Sunday, Rep. Park Sung-hoon of the main opposition People Power Party said in a statement that the ruling bloc has "waged war against individual investors out of nowhere" through the proposed tax code revision, which he blamed for the Kospi's fall by 3.88 percent on Friday from the previous day's close, marking the sharpest decline in four months. About 99.17 trillion won ($71.36 billion) of market cap evaporated solely on Friday from 850 listed companies on the Kospi combined, according to the Korea Exchange, a day after the liberal administration on Thursday introduced a tax code revision to broaden the tax base. Also, over 90,000 people as of Sunday afternoon had signed an online petition posted just three days earlier Thursday to call on the ruling bloc to slam the brakes on the tax bill revision ― meeting the requirement of 50,000 signatures within 30 days for the matter to be brought to a parliamentary review. The proposed revision of the Income Tax Act indicates that those identified by year-end as stock investors holding at least 1 billion won in a listed company's shares will be levied a capital gains tax of at least 20 percent upon taking profits from selling shares until the end of the company's business year that follows. The same investor's losses in another company's stocks cannot be used to offset capital gains taxes from his or her profits, under South Korea's tax code. The online petitioner warned of a situation in which investors rush to sell off securities as the end of the year approaches ― even at a loss ― to offset capital gains tax, which it said would stymie the moderate rise of Kospi. "Is it realistic (to predict) that you'll be holding 1 billion won worth of shares (of a company by the year-end)? Most investors will begin selling shares when their stock holdings of a company begin to value about 700 or 800 million won," read the petition. Currently, those holding shares worth 5 billion won or more are imposed capital gains tax for their sales of securities. This follows the former administration's move by disgraced ex-President Yoon Suk Yeol to raise the bar for investors in South Korean companies to become a "major stockholder" under the Income Tax Act. In December 2023, the minimum threshold for a stock investor to be classified a "major stockholder" for capital gains taxation was raised to 5 billion won, up from the 1 billion won mark set in April 2020. "Am I paying (more taxes) because I'm holding a greater amount of stocks, not because I took bigger gains? If so, I'll surely exit the South Korean stock markets and turn to ones in the United States," the petition also read. The proposed tax code revision ― predicted to collect 35.6 trillion won in taxes ― also suggests that the securities transaction tax rate be raised from 0.15 percent to 0.2 percent. Na Jeong-hwan, a strategist at NH Investment & Securities, said in a note to investors Friday that fears of tax code changes "sparked questions about the government's policy to boost the stock market." The ruling bloc appears to have mixed views over the new tax code proposal. Democratic Party Rep. Jin Sung-joon, who leads the party's policymaking process, downplayed concerns that the tax code changes could stoke a bear turn in the stock market. Referring to an underperformance in domestic stocks under the Yoon administration, despite the eased capital gains tax rule, Jin said via Facebook on Saturday, "Many investors and experts are saying that if we change who is to be levied capital gains by rolling back (the tax relief of the Yoon administration) our stock market could experience a collapse, but precedents suggest otherwise." Presidential spokesperson Kang Yu-jung also played down a connection between the fluctuation in the stock market and the tax code revision announcement, saying in a briefing Friday that a cause-and-effect analysis on Friday's stock slide "must be carried out more delicately." However, before Friday's plunge, Rep. Lee So-young of the Democratic Party in a Facebook post Thursday raised doubts that those holding 1 billion won of stocks of a company should be deemed a major stockholder for capital gains taxation, adding that the move could disrupt investors, while the degree of increase in the tax revenue from the changes remains unclear. Rep. Kim Han-kyu of the Democratic Party also said Saturday that striking fairness in taxation schemes is important, but now is the time to focus on the Lee administration's campaign pledge for the Kospi to reach 5,000. The Kospi stood at 3,119.41 points at Friday's close.
Korea Herald
17 hours ago
- Korea Herald
Amorepacific glows abroad, sending profit soaring sixfold
Amorepacific Holdings, the parent company of South Korean beauty giant Amorepacific, reported a more than sixfold increase in second-quarter operating profit on the back of robust overseas expansion and solid gains in the domestic market. In a regulatory filing on Friday, the company posted an operating profit of 80.1 billion won ($57.6 million) for the April to June period, up 555.5 percent from 12.2 billion won a year earlier. Consolidated revenue rose 8.9 percent on-year to 1.09 trillion won. The group's flagship subsidiary, Amorepacific, led the gains with steady growth in Korea's beauty sector and continued momentum in overseas markets, reporting an 11.1 percent rise in revenue and more than a 17-fold increase in operating profit from a year earlier. Operating profit from its overseas operations soared 611 percent to 36 billion won, with domestic profit also rising 164 percent to 40.2 billion won. In regional breakdowns, revenue in the Greater China region surged 23 percent, driven by business model restructuring, according to the company. In the Americas, sales rose 10 percent, while sales in Europe, the Middle East and Africa climbed 18 percent. Among key subsidiaries, Etude saw a 196 percent rise in operating profit to 2.8 billion won, while Innisfree posted an 81 percent gain in operating profit despite a 9 percent decline in revenue to 53.2 billion won. 'We are actively pursuing a global rebalancing strategy,' an Amorepacific Holdings official said. 'This includes strengthening distribution partnerships in core overseas markets and exploring diverse business models."
